

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

02 FEB -8 PM 12: 2

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>Novartis</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>701 Pennsylvania Ave. NW</b> Suite <b>725</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20004</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>Burt Rosen</b>	Telephone <b>202-638-7429</b>	E-mail (optional)	5. Senate ID # <b>9204-12</b>
7. Client Name <input checked="" type="checkbox"/> Self <b>Novartis Corporation</b>			6. House ID # <b>33589000</b>

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  **OR** Year End (July 1-Dec)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_ 11. No Lobbyi

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,180,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of <input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definiti <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 the Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162( Internal Revenue Code

Signature \_\_\_\_\_



Date \_\_\_\_\_

2/7/01



Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code BUD (one per page)


16. Specific Lobbying issues  
**Appropriations: FDA**  
**Appropriations: USDA**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Bumbaugh, Deborah</b>	
<b>Drake, David</b>	
<b>Elkin, James</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit.**

Signature  Date 2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)


16. Specific Lobbying issues  
**S.754/H.R.1063, Increasing Ability to Enforce Antitrust Laws,  
S.812/H.R.1862, Greater Access to Affordable Pharmaceuticals Act,**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**House of Representatives  
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Casserly, Dan</b>	
<b>Drake, David</b>	
<b>Elkin, James</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit**

Signature  Date 2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code FOO (one per page)


16. Specific Lobbying issues  
**National Uniformity for Food  
Genetically Engineered Food Right to Know Act  
Country of Origin Labeling  
GMO Labeling**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**Department of Agriculture  
Environmental Protection Agency  
Food & Drug Administration  
House of Representatives  
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Drake, David</b>	
<b>Elkin, James</b>	
<b>Haller, Sarah</b>	
<b>Rosen, Burt</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit.**

Signature  Date 2/7/02





Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 1387, Drug Availability and Health Care Access Improvement Act of 2001,
- H.R.1530, Prescription Drug Competition Act of 2001,
- H.R.1624/S.913, Access to Cancer Therapies Act of 2001,
- S. 1239 , Medicare Rx Drug Discount and Security Act of 2001,
- S.10 , Medicare Prescription Drug Coverage Act of 2001,
- S.1135, Medicare Reform Act of 2001,
- S.1185 , Seniors Prescription Insurance Coverage Equity Act of 2001,
- S.838 IS, Better Pharmaceuticals for Children Act ,
- S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,
- S.982 IS /H.R.2058 IH, Medicare Wellness Act of 2001,

17. House(s) of Congress and Federal agencies contacted  Check if None  
**Drug Enforcement Administration**  
**Food & Drug Administration**  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Bumbaugh, Deborah</b>	
<b>Casserly, Dan</b>	
<b>Drake, David</b>	
<b>Elkin, James</b>	
<b>Haller, Sarah</b>	
<b>Rosen, Burt</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit.**

Signature  Date 2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	<p>Medicare Prescription Drugs Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act (S.11) Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bills Prospective Payment System Gene Therapy Drug Reimportation Medicare Reform Agriculture Appropriations 2001 - Drug Reimportation Agriculture Appropriation 2001 (FDA funding) Stem Cell Research Pediatric Exclusivity Direct-to-Consumer Advertising PDUFA The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draf President Bush's "Helping Hand" proposal</p>



Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**H.R. 1530, Prescription Drug Competition Act of 2001,  
H.R.1387, Drug Availability and Health Care Access Improvement Act of 2001,  
HR1624/S913, Access to Cancer Therapies Act,  
S. 10, Medicare Prescription Drug Coverage Act of 2001 ,  
S.1135, Medicare Reform Act of 2001,  
S.1185, Seniors Prescription Insurance Coverage Equity Act of 2001,  
S.1239, Medicare Rx Drug Discount & Security Act of 2001,  
S.880/H.R.1839, Immunosuppressive Drug Coverage Act of 2001,  
S.982 IS/H.R. 2058 IH, Medicare Wellness Act of 2001,**

17. House(s) of Congress and Federal agencies contacted  Check if None

**Department of Health & Human Services  
Food & Drug Administration  
House of Representatives  
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Bumbaugh, Deborah</b>	
<b>Casserly, Dan</b>	
<b>Drake, David</b>	
<b>Elkin, James</b>	
<b>Haller, Sarah</b>	
<b>Rosen, Burt</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit.**

Signature



Date

2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	<b>Lobbying Issues</b>	<b>Medicare Prescription Drug &amp; Modernization Act The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draf President Bush's "Helping Hand" proposal Prospective Payment System Medicare Reform</b>





Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)


16. Specific Lobbying issues  
**R&D Tax Credit**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**House of Representatives**  
**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Drake, David</b>	
<b>Elkin, James</b>	
<b>Haller, Sarah</b>	
<b>Rosen, Burt</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None  
**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Co too Novartis AG, as its parent, will benefit.**

Signature  Date 2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

- 16. Specific Lobbying issues
  - Economic Sanctions**
  - SRM Ban/BSE**
  - China/World Trade Organization**
  - Fast Track Negotiating Authority**
  - Capital Market Sanctions**

17. House(s) of Congress and Federal agencies contacted  Check if None


- Department of Commerce**
- Food & Drug Administration**
- House of Representatives**
- Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Haller, Sarah</b>	
<b>Rosen, Burt</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Cor too Novartis AG, as its parent, will benefit.**

Signature  Date 2/7/02



Registrant Name: Novartis

Client Name: Novartis Corporation

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client  
**King, Rachel**

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bus (city and state or cou

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client


**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrar or affiliated organization

Signature \_\_\_\_\_



Date \_\_\_\_\_

2/7/05

